The JAK2V617F tyrosine kinase mutation in blood donors with upper-limit haematocrit levels

Blood Transfusion

Volumn 7, Issue 2, 2009, Pages 111-116

  Tagariello, Giuseppe ^a,b   Di Gaetano, Rosanna ^a   Sartori, Roberto ^a   Zanotto, Daniela ^a   Belvini, Donata ^a   Radossi, Paolo ^a   Risato, Renzo ^a   Roveroni, Giovanni ^a   Salviato, Roberta ^a   Tassinari, Cristina ^a   Toffano, Nunzio ^a  

^a Azienda ULSS   (Italy)

^b Ospedale di Castelfranco Veneto   (Italy)

Author keywords

Blood donors; Haematocrit; JAK2 mutations; Myeloproliferative disorder; Polycythaemia vera

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2;

ADULT; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; FEMALE; GENE MUTATION; HEMATOCRIT; HUMAN; MALE; POLYCYTHEMIA VERA; PREVALENCE;

ADULT; BLOOD DONORS; CHROMOSOMES, HUMAN, PAIR 9; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENETIC SCREENING; HEMATOCRIT; HUMANS; INCIDENCE; ITALY; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; POLYCYTHEMIA VERA; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 66349136312     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0049-08     Document Type: Article

References (28)

1. Davey RJ. The blood centre as a community health resource. Vox Sang 2006; 91: 206-213 (Pubitemid 44337277)
2. Zanella A, Silvani C, Banfi P, et al. Screening and evaluation of blood donors with upper-limit hematocrit levels. Transfusion 1987; 27: 485-487 (Pubitemid 18006489)
3. Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk Lymphoma 2006; 47: 381-396 (Pubitemid 43102085)
4. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003; 82: 148-152 (Pubitemid 36700994)
5. Finazzi G. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol 2004; 52: 285-290 (Pubitemid 38813224)
6. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224-2232 (Pubitemid 46218714)
7. Stuart BJ, Viera AJ. Polycythemia vera. Am Fam Physician 2004; 69:2139-2144 (Pubitemid 38608049)
8. Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol 2005;42: 206-220 (Pubitemid 41400662)
9. Baxter RJ, Scott LM, Campbell PJ, et al., Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061
10. James C, Ugo V, Le Couedic SP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005; 434: 1144-1148 (Pubitemid 40663494)
11. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790 (Pubitemid 40570926)
12. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7: 387-397 (Pubitemid 40544655)
13. Zhao ZJ, Vainchenker W, Krantz SB, et al. Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol 2005; 42: 221-229 (Pubitemid 41400663)
14. Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005;80: 947-958 (Pubitemid 40911470)
15. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006;34: 240-245
16. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007 15;110:1092-1097 (Pubitemid 47281402)
17. Chang CC. BCR/ABL-negative chronic myeloproliferative disorders: JAK2 mutation and beyond. Arch Path Lab Med 2006; 130 1123-1125 (Pubitemid 44168779)
18. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006; 20: 350-353 (Pubitemid 43148676)
19. Michiels JJ, De Raeve H, Berneman Z, et al. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost 2006; 32: 307-340
20. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168 (Pubitemid 41291734)
21. Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med 2003; 139: 470-475 (Pubitemid 38124571)
22. Randi ML, Rossi C, Barbone E, et al. Myeloproliferative disease in patients with a history of multiple blood donations: a report of 8 cases. Haematologica 1994; 79: 137-140 (Pubitemid 24175007)
23. Merk K, Mattsson A, Holm G, et al. The incidence of cancer among blood donors. Int J Epidemiol 1990; 19: 505-509 (Pubitemid 20331791)
24. Xu X, Zhang Q, Luo J, et al. JAK2(V617F): Prevalence in a large Chinese hospital population. Blood 2007; 109: 339-342 (Pubitemid 46053075)
25. Passamonti F, Rumi E, Pietra D, et al. JAK2 (V617F) mutation in healthy individuals. Br J Haematol 2007;136: 678-679 (Pubitemid 46148209)
26. Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362-3367 (Pubitemid 28492345)
27. Tefferi A. The rise and fall of red cell mass measurement in polycythemia vera Curr Hematol Rep 2005; 4: 213-217
28. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302